SEC Form 4 · accession 0001209191-17-020909
CORCEPT THERAPEUTICS INC · CORT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Patrick G Enright
Director
Period of report
Mar 13, 2017
Accepted (ET)
Mar 15, 2017 · 6:45 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001088856
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | Mar 13, 2017 | S | 20,568 | $11.1292 | D | 7,534,014 | I | By LVP |
| Common StockF1,F2 | Mar 13, 2017 | S | 412 | $11.1291 | D | 151,008 | I | By LCA |
| Common StockF3,F2 | Mar 14, 2017 | S | 294,105 | $10.0089 | D | 7,239,909 | I | By LVP |
| Common StockF3,F2 | Mar 14, 2017 | S | 5,895 | $10.0089 | D | 145,113 | I | By LCA |
| Common StockF4,F2 | Mar 15, 2017 | S | 273,537 | $10.2386 | D | 6,966,372 | I | By LVP |
| Common StockF4,F2 | Mar 15, 2017 | S | 5,483 | $10.2372 | D | 139,630 | I | By LCA |
| Common Stock | holding | — | — | — | 204,210 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Reflects sales of common stock of the Issuer executed in multiple transactions at prices ranging from $11.10 to $11.305. The price reported reflects the weighted-average price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
- F2Reflects shares of common stock of the Issuer held of record by Longitude Venture Partners, L.P. ("LVP") and Longitude Capital Partners, L.P. ("LCA"). Mr. Enright is a managing member of Longitude Capital Partners, LLC, the sole general partner of LVP and LCA. Mr. Enright disclaims beneficial ownership of the securities of the Issuer held of record by LVP and LCA, except to the extent of his pecuniary interest therein.
- F3Reflects sales of common stock of the Issuer executed in multiple transactions at prices ranging from $9.90 to $10.37. The price reported reflects the weighted-average price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
- F4Reflects sales of common stock of the Issuer executed in multiple transactions at prices ranging from $10.14 to $10.36. The price reported reflects the weighted-average price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.